News | September 19, 2012

First Atrial Fibrillation Patient Treated With Innovative Ablation Procedure

September 19, 2012 — This past week, surgeons and cardiologists at Sentara Heart Hospital were the first in the world to begin performing surgeries in the Dual Epicardial Endocardial Persistent Atrial Fibrillation (AF) Study (Staged DEEP) feasibility trial. Cardiothoracic surgeon collaborator Jonathan Philpott, M.D., director of the Sentara Atrial Fibrillation Surgery Program, and cardiac electrophysiologist collaborator Ian Woollett, M.D., of Cardiovascular Associates, performed the first procedure.

The Staged DEEP trial is a U.S. Food and Drug Administration (FDA)-approved pilot study sponsored by cardiac device manufacturer AtriCure Inc. The study is designed to evaluate the safety and efficacy of a combined procedure whereby the surgeon creates lines of block on the outside of the heart, working through tiny chest incisions. During the same hospital stay, an electrophysiologist tests the surgical lines and then completes additional ablation lines using tiny catheters within the heart. There are currently no FDA-approved devices for the minimally invasive surgical (MIS) or endocardial treatment of persistent forms of AF, and current options yield very limited success.

"We believe that this staged hybrid procedure has the potential to represent an important advancement in the treatment of persistent forms of AF," said Robert Bernstein, M.D., an electrophysiologist in Norfolk, Va., and one of four electrophysiologists at Sentara collaborating in the trial. "Our initial experience with this hybrid procedure suggests that it represents a highly promising AF treatment."

AF is the most common irregular heartbeat affecting more than 2 million people in the United States. It is characterized by heart palpitations, dizziness and shortness of breath. Persistent forms of AF comprise roughly half of the AF patient population, and this number is expected to increase significantly due to the progressive nature of the disease and the aging population.

Said Philpott: “Our preliminary experience with this procedure is very encouraging. The partnership between the electrophysiologist and the cardiac surgeon in the hybrid procedure leverages the skills and technologies of each specialist, providing patients with the most comprehensive ablation and mapping procedure available.”

“Staging these procedures gives the cardiac surgeon and the electrophysiologist the flexibility to work within their own familiar environments, making each team more efficient and effective,” added Woollett

For more information: www.sentara.com

Related Content

Biosense Webster Announces Initial Results From First-in-Human QDOT-FAST Study
News | Ablation Systems | May 16, 2019
Johnson & Johnson Medical Devices Companies announced that Biosense Webster, Inc.’s QDot Micro catheter...
CardioFocus Announces Results From HeartLight X3 Ablation System Pivotal Study
News | Ablation Systems | May 16, 2019
CardioFocus Inc. announced the presentation of results from its pivotal confirmatory study evaluating the HeartLight X3...
New Global Consensus Statement Addresses Catheter Ablation of Ventricular Arrhythmias
News | Ablation Systems | May 14, 2019
The Heart Rhythm Society (HRS) in partnership with three other professional societies issued an international consensus...
Netherlands Hospital to Install State-of-the-Art MRI Ablation Center
News | Ablation Systems | May 13, 2019
Imricor announced the signing of a commercial agreement with the Haga Hospital in The Hague, Netherlands to outfit a...
A CyberHeart cardiac ablation radiotherapy treatment plan showing where the radiation beam will ablate for a noninvasive pulmonary vein isolation procedure. Varian acquires, buys, purchases Cyberheart.

A CyberHeart cardiac ablation radiotherapy treatment plan showing where the radiation beams will ablate for a noninvasive pulmonary vein isolation procedure to treat an arrhythmia.

Feature | Ablation Systems | May 10, 2019 | Dave Fornell, Editor
May 10, 2019 — Radiation oncology vendor Varian announced it acquired the start-up company CyberHeart, which has deve
Ablation Reduces Risk of Dementia in Patients With AFib and Carotid Artery Disease
News | Ablation Systems | May 08, 2019
Even though many medical practitioners may opt not to perform procedures on higher-risk patients, new research finds it...
CardioFocus Announces European CE Mark Approval Of HeartLight X3 System
News | Ablation Systems | April 16, 2019
CardioFocus Inc. announced the European CE Mark approval of the HeartLight X3 Endoscopic Ablation System.
First Patient Treated With QDot Micro Ablation Catheter
News | Ablation Systems | February 04, 2019
Biosense Webster has enrolled and treated the first patient in its U.S. Investigational Device Exemption (IDE) study...
FDA Approves TactiCath Contact Force Ablation Catheter, Sensor Enabled
Technology | Ablation Systems | January 21, 2019
Abbott announced U.S. Food and Drug Administration (FDA) approval of the TactiCath Contact Force Ablation Catheter,...
First Patient Treated in STELLAR Atrial Fibrillation IDE Study
News | Ablation Systems | November 30, 2018
Johnson & Johnson Medical Devices Companies announced that Biosense Webster Inc. has enrolled and treated the first...
Overlay Init